Abstract
The use of inhaled corticosteroids (ICSs) plays a key role in the treatment of asthmatic patients, and international guidelines have designated ICSs as an early maintenance therapy in controlling asthma symptoms. When asthmatic patients remain symptomatic on ICSs, one common option is to add a long-acting beta2 agonist (LABA) to the maintenance treatment. Fixed combination inhalers that contain both an ICS and a LABA have been popular for both chronic obstructive pulmonary disease (COPD) and asthma. Historically, these inhalers have been dosed twice daily. However, currently, there is a once-daily combination therapy with the ICS fluticasone furoate (FF) and the LABA vilanterol trifenatate (VI) with indications for use in both COPD and asthma. This dry powder inhaler (DPI) comes in two doses of FF (100 or 200 µg) both combined with VI (25 µg). This article reviews the clinical trial data for FF, VI and FF/VI combination inhalers and documents the efficacy and safety of once-daily inhaled maintenance therapy by DPI in asthmatic patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4047-4060 |
| Number of pages | 14 |
| Journal | Drug Design, Development and Therapy |
| Volume | 10 |
| DOIs | |
| State | Published - Dec 14 2016 |
Fingerprint
Keywords
- Asthma
- Combined inhaler
- Dry powder inhaler
- Fluticasone furoate/vilanterol trifenatate
- Inhaled corticosteroid
- Long-acting beta agonist
- Persistent asthma
ASJC Scopus subject areas
- Pharmacology
- Pharmaceutical Science
- Drug Discovery
Cite this
Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma : Design, development and place in therapy. / Albertson, Timothy E; Bullick, Samuel W.; Schivo, Michael; Sutter, Mark E.
In: Drug Design, Development and Therapy, Vol. 10, 14.12.2016, p. 4047-4060.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma
T2 - Design, development and place in therapy
AU - Albertson, Timothy E
AU - Bullick, Samuel W.
AU - Schivo, Michael
AU - Sutter, Mark E
PY - 2016/12/14
Y1 - 2016/12/14
N2 - The use of inhaled corticosteroids (ICSs) plays a key role in the treatment of asthmatic patients, and international guidelines have designated ICSs as an early maintenance therapy in controlling asthma symptoms. When asthmatic patients remain symptomatic on ICSs, one common option is to add a long-acting beta2 agonist (LABA) to the maintenance treatment. Fixed combination inhalers that contain both an ICS and a LABA have been popular for both chronic obstructive pulmonary disease (COPD) and asthma. Historically, these inhalers have been dosed twice daily. However, currently, there is a once-daily combination therapy with the ICS fluticasone furoate (FF) and the LABA vilanterol trifenatate (VI) with indications for use in both COPD and asthma. This dry powder inhaler (DPI) comes in two doses of FF (100 or 200 µg) both combined with VI (25 µg). This article reviews the clinical trial data for FF, VI and FF/VI combination inhalers and documents the efficacy and safety of once-daily inhaled maintenance therapy by DPI in asthmatic patients.
AB - The use of inhaled corticosteroids (ICSs) plays a key role in the treatment of asthmatic patients, and international guidelines have designated ICSs as an early maintenance therapy in controlling asthma symptoms. When asthmatic patients remain symptomatic on ICSs, one common option is to add a long-acting beta2 agonist (LABA) to the maintenance treatment. Fixed combination inhalers that contain both an ICS and a LABA have been popular for both chronic obstructive pulmonary disease (COPD) and asthma. Historically, these inhalers have been dosed twice daily. However, currently, there is a once-daily combination therapy with the ICS fluticasone furoate (FF) and the LABA vilanterol trifenatate (VI) with indications for use in both COPD and asthma. This dry powder inhaler (DPI) comes in two doses of FF (100 or 200 µg) both combined with VI (25 µg). This article reviews the clinical trial data for FF, VI and FF/VI combination inhalers and documents the efficacy and safety of once-daily inhaled maintenance therapy by DPI in asthmatic patients.
KW - Asthma
KW - Combined inhaler
KW - Dry powder inhaler
KW - Fluticasone furoate/vilanterol trifenatate
KW - Inhaled corticosteroid
KW - Long-acting beta agonist
KW - Persistent asthma
UR - http://www.scopus.com/inward/record.url?scp=85007483139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007483139&partnerID=8YFLogxK
U2 - 10.2147/DDDT.S113573
DO - 10.2147/DDDT.S113573
M3 - Review article
C2 - 28008228
AN - SCOPUS:85007483139
VL - 10
SP - 4047
EP - 4060
JO - Drug Design, Development and Therapy
JF - Drug Design, Development and Therapy
SN - 1177-8881
ER -